Arcturus Therapeutics (ARCT) to Release Earnings on Monday

Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) will be announcing its earnings results after the market closes on Monday, May 9th. Analysts expect the company to announce earnings of ($1.29) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) last announced its quarterly earnings results on Monday, February 28th. The biotechnology company reported ($1.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.77) by $0.30. Arcturus Therapeutics had a negative return on equity of 61.88% and a negative net margin of 1,647.99%. The company had revenue of $5.79 million during the quarter, compared to analysts’ expectations of $12.90 million. During the same quarter in the previous year, the firm earned ($1.25) earnings per share. On average, analysts expect Arcturus Therapeutics to post $-5 EPS for the current fiscal year and $4 EPS for the next fiscal year.

ARCT stock opened at $19.38 on Monday. The company has a 50-day moving average of $23.95 and a two-hundred day moving average of $31.28. Arcturus Therapeutics has a 52-week low of $16.93 and a 52-week high of $65.00.

ARCT has been the subject of a number of research reports. Wells Fargo & Company reduced their price objective on Arcturus Therapeutics from $107.00 to $105.00 and set an “overweight” rating for the company in a research report on Friday, March 25th. Citigroup cut shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $86.00 to $29.00 in a research note on Thursday, April 21st. Cantor Fitzgerald lowered their price target on Arcturus Therapeutics from $93.00 to $86.00 in a report on Tuesday, March 1st. Barclays decreased their price target on shares of Arcturus Therapeutics from $31.00 to $21.00 in a research note on Tuesday, March 1st. Finally, Raymond James upgraded shares of Arcturus Therapeutics from an “underperform” rating to a “market perform” rating in a research note on Monday, January 31st. Six investment analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $43.63.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Nuveen Asset Management LLC boosted its stake in Arcturus Therapeutics by 140.7% in the fourth quarter. Nuveen Asset Management LLC now owns 94,925 shares of the biotechnology company’s stock valued at $3,513,000 after acquiring an additional 55,492 shares in the last quarter. California State Teachers Retirement System raised its position in Arcturus Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 29,197 shares of the biotechnology company’s stock valued at $1,081,000 after purchasing an additional 557 shares during the period. Renaissance Technologies LLC purchased a new position in Arcturus Therapeutics in the fourth quarter valued at $988,000. Credit Suisse AG boosted its position in shares of Arcturus Therapeutics by 5.8% during the 4th quarter. Credit Suisse AG now owns 26,004 shares of the biotechnology company’s stock worth $963,000 after acquiring an additional 1,433 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Arcturus Therapeutics by 124.8% in the 4th quarter. Barclays PLC now owns 25,623 shares of the biotechnology company’s stock valued at $949,000 after purchasing an additional 14,226 shares during the last quarter. 80.10% of the stock is currently owned by institutional investors.

About Arcturus Therapeutics (Get Rating)

Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.

See Also